Abstract
PURPOSE Although smoking by patients with cancer and survivors causes adverse outcomes, many patients with cancer do not receive access to evidence-based tobacco use treatment. The purpose of this article is to report on delivery of tobacco use treatment to patients with cancer using a state-supported Quitline. METHODS Statewide agencies in Michigan partnered with the Michigan Oncology Quality Consortium to develop and implement a clinical quality improvement initiative with the goal of addressing tobacco use by patients with cancer across Michigan oncology practices. The collaborative designed an opt-out approach for identifying tobacco users and referring them to the Michigan Tobacco Quitline (hereafter known as Quitline) within participating practices. As the initiative progressed, patients with cancer who were not referred through the initiative also became eligible for enrollment in the Quitline program. RESULTS A total of 4,347 patients with cancer enrolled in the Quitline between 2012 and 2017, and annual referrals from oncology practices increased from 364 (5% of Quitline participants) to 876 (17% of Quitline participants). The 2013-2016 Michigan Behavioral Risk Factor Surveillance System also demonstrated an increase from 60% to 80% of cancer survivors receiving smoking cessation resources. Of 3,892 patients with cancer who had Quitline follow-up data through 2017, 79% completed one or more counseling calls. The 6-month self-reported quit rate for patients with cancer assessed between 2013 and 2016 was 26%. CONCLUSION Using statewide resources to increase access to evidence-based smoking cessation assistance to patients with cancer is achievable. In an increasingly cost-conscious health care environment, collaborative initiatives that use or enhance existing resources should be considered and refined to deliver effective evidence-based care.
| Original language | English |
|---|---|
| Pages (from-to) | E549-E556 |
| Journal | JCO Oncology Practice |
| Volume | 16 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 1 2020 |
Bibliographical note
Publisher Copyright:Copyright © 2020 American Society of Clinical Oncology. All rights reserved.
Funding
Supported by Cooperative Agreements No. NU58DP006109, DP003040, and NU58DP005349 from the Centers for Disease Control and Prevention. We thank Jane Severson for leading the design and implementation of this collaborative and the leaders and staff of the Michigan Department of Health and Human Services and Michigan Oncology Quality Consortium for developing, implementing and maintaining the initiative. We also thank the National Jewish Health Quitline coaches, management, and evaluation team for delivering tobacco treatment to Michigan residents, Blue Cross Blue Shield of Michigan, whose support is valued and appreciated, and the participating hematology/oncology clinics that work daily to improve outcomes for people living with cancer. This initiative was supported by Cooperative Agreements No. NU58DP006109, DP003040, and NU58DP005349 from the Centers for Disease Control and Prevention. Michigan Oncology Quality Consortium is funded by Blue Cross Blue Shield of Michigan. Supported by Cooperative Agreements No. NU58DP006109, DP003040, and NU58DP005349 from the Centers for Disease Control and Prevention. To address tobacco use in patients with cancer, a clinical quality improvement project was conceptualized in 2011 to develop and implement a statewide program to increase access to evidence-based tobacco treatment at oncology practices throughout the state of Michigan. An initial analysis of tobacco assessment and treatment documented by Michigan oncology practices demonstrated that less than 15% of patients reporting tobacco use were referred for treatment, less than the nationally reported Quality Oncology Practice Initiative (QOPI) average of 47%.13 To address this gap, a collaborative was formed between the Cancer and Tobacco Control Programs at the Michigan Department of Health and Human Services (MDHHS), the Michigan Oncology Quality Consortium (MOQC), the Michigan Cancer Consortium (MCC), and National Jewish Health (NJH). The MCC is a statewide consortium of more than 100 organizations dedicated to reducing the cancer burden in Michigan that is supported by the MDHHS Cancer Prevention and Control Program. The MDHHS Tobacco Control Program supports and evaluates the Quitline. NJH is the Quitline vendor that provides tobacco treatment counseling by telephone and pharmacotherapy to patients, as well as technical assistance and data to referring providers. MOQC is a Collaborative Quality Initiative aligned with the University of Michigan Rogel Cancer Center and funded by Blue Cross Blue Shield of Michigan. MOQC uses data gathered from oncology practices as part of the national QOPI program to identify areas for improving the care of patients with cancer in Michigan.
| Funders |
|---|
| Blue Cross Blue Shield of Michigan |
| Michigan Oncology Quality Consortium |
| National Jewish Health Quitline coaches |
| Centers for Disease Control and Prevention |
| Blue Cross Blue Shield of Michigan Foundation |
| MICHIGAN DEPARTMENT OF HEALTH AND HUMAN SERVICES |
| Rogel Cancer Center, University of Michigan |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
ASJC Scopus subject areas
- Oncology
- Health Policy
- Oncology(nursing)
Fingerprint
Dive into the research topics of 'Using a Quitline to Deliver Opt-Out Smoking Cessation for Cancer Patients'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver